Program
deucravacitinib
Also written as “BMS-986165”, “Deucravacitinib” and “BMS-986165 Tablet”.
Its studies are mostly in Psoriasis · Lupus Erythematosus, Systemic · Arthritis, Psoriatic · Crohn Disease · Colitis, Ulcerative, led by 2 companies.
Drug pageDeucravacitinib: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 5912 open or running | phase 4since Jul 27, 2022 | Oct 3, 2016 | Nov 18, 2026phase 3 · NCT05946941 |
| AbbVie | 10 open or running | phase 4since Mar 21, 2024 | Mar 21, 2024 | none ahead |
Also a collaborator on its studies: Covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2020Named deucravacitinibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, BMS-986165
- Mar 21, 2024First study: phase 4 study in Moderate Plaque PsoriasisFirst studyNCT06333860 · 393 enrolled · United States, Australia, Belgium and more
TargetBeta
“Tyrosine-protein kinase TYK2 negative allosteric modulator”ChEMBL 37, by rule
Other programs on TYK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| D-2570rule | InventisBio | phase 3 | 13 |
| HS-10374 | Hansoh Pharmaceutical Group | phase 3 | 6 |
| TQH3906 | Sino Biopharmaceutical | phase 3 | 6 |
| FXS5626 | Fosun Pharma | phase 3 | 3 |
| TYK2 Inhibitorrule | usynova-pharmaceuticals-ltd | no phase | 1 |
Studies
The one study AbbVie leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06333860Moderate Plaque Psoriasis · United States, Australia, Belgium and more | 4 | Completed | Mar 19, 2026 | 393 |
How it is read
Names in the registry
- “BMS-986165”, 34 entries
- “Deucravacitinib”, 21 entries
- “BMS-986165 Tablet”, 2 entries
- “BMS-986165 Dose A”, 1 entry
- “BMS-986165 Dose B”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 16 studies
- Lupus Erythematosus, Systemic, 9 studies
- Arthritis, Psoriatic, 4 studies
- Crohn Disease, 2 studies
- Colitis, Ulcerative, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.